Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 9Endocrine 9Thoracic 2Plasma cell 2Other hematologic neoplasm 2Gastrointestinal 2CNS 2Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Melanoma 10Glioma 9Brain Neoplasms 9Neoplasms 3Multiple Myeloma 3Histiocytosis, Langerhans-Cell 3Glioblastoma 3Astrocytoma 3Thyroid Carcinoma, Anaplastic 2Ovarian Neoplasms 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Lung Neoplasms 2Hematologic Neoplasms 2Ganglioneuroma 2Ganglioglioma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Nonseminomatous germ cell tumor 1

Interventions

trametinib 2dabrafenib 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1sargramostim 1cobimetinib 1cabozantinib 1atezolizumab 1aldesleukin 1Vemurafenib 1Trastuzumab 1Tamoxifen 1Semaxinib 1Radiotherapy 1Paclitaxel 1Gefitinib 1Doxorubicin 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × dabrafenib × CNS × Clear all
NCT07440290 2026-02-27

DETERMINE

Cancer Research UK

Phase 2/3 Not yet recruiting
30 enrolled
CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡